Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel treatment for glioblastoma: integrin inhibition.
Chamberlain MC, Cloughsey T, Reardon DA, Wen PY. Chamberlain MC, et al. Expert Rev Neurother. 2012 Apr;12(4):421-35. doi: 10.1586/ern.11.188. Expert Rev Neurother. 2012. PMID: 22449214 Review.
Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.
Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA. Chamberlain M, et al. Neuro Oncol. 2014 Sep;16(9):1176-85. doi: 10.1093/neuonc/nou089. Epub 2014 May 27. Neuro Oncol. 2014. PMID: 24867803 Free PMC article. Review.
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. Nayak L, et al. Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Neuro Oncol. 2017. PMID: 28453751 Free PMC article. Review.
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Ellingson BM, et al. Neuro Oncol. 2018 Sep 3;20(10):1411-1418. doi: 10.1093/neuonc/noy054. Neuro Oncol. 2018. PMID: 29660005 Free PMC article. Clinical Trial.
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. Schiff D, et al. Among authors: chamberlain mc. Cancer. 2016 Feb 15;122(4):582-7. doi: 10.1002/cncr.29798. Epub 2015 Nov 20. Cancer. 2016. PMID: 26588662 Free article. Clinical Trial.
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY. Arvold ND, et al. Among authors: chamberlain mc. Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056. Neuro Oncol. 2018. PMID: 29788429 Free PMC article. Review.
383 results